Dyne Therapeutics Inc

For the period ended Dec 31, 2023. Filed Mar 5, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 5, 2024

DYN$18.62+3.0%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets

	December 31,
(in thousands, except share and per share data)	2023	2022
Assets
Current assets:
Cash and cash equivalents	$121,626	$172,147
Marketable securities	1,474	83,865
Prepaid expenses and other current assets	6,275	9,582
Total current assets	129,375	265,594
Property and equipment, net	4,780	5,945
Right-of-use assets	28,612	32,467
Restricted cash	2,315	2,319
Total assets	$165,082	$306,325
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$22,936	$5,259
Accrued expenses and other current liabilities	23,439	18,219
Lease liabilities	4,720	4,610
Total current liabilities	51,095	28,088
Lease liabilities, net of current portion	22,695	25,873
Total liabilities	73,790	53,961
Commitments and contingencies (Note 10)
Stockholders’ equity
Preferred stock, $0.0001 par value; 10,000,000 shares authorized at December 31, 2023 and 2022	—	—
Common stock, $0.0001 par value; 200,000,000 shares authorized at December 31, 2023 and 2022; 61,468,743 and 55,636,505 shares issued and outstanding at December 31, 2023 and 2022, respectively	6	6
Additional paid-in capital	723,796	649,502
Accumulated other comprehensive loss	—	(571)
Accumulated deficit	(632,510)	(396,573)
Total stockholders’ equity	91,292	252,364
Total liabilities and stockholders’ equity	$165,082	$306,325

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.